Estradiol Exerts Neuroprotective Actions Against Ischemic Brain Injury: Insights Derived from Animal Models

Endocrine ◽  
2003 ◽  
Vol 21 (1) ◽  
pp. 11-16 ◽  
Author(s):  
Phyllis M. Wise
Keyword(s):  
Brain Injury ◽  
Animal Models ◽  
Ischemic Brain Injury ◽  
Ischemic Brain ◽  
Neuroprotective Actions

scholarly journals Neuroprotection of Early Locomotor Exercise Poststroke: Evidence From Animal Studies

2015 ◽  
Vol 42 (4) ◽  
pp. 213-220 ◽  
Author(s):  
Pengyue Zhang ◽  
Jia Xianglei ◽  
Yang Hongbo ◽  
Jichuan Zhang ◽  
Ce Xu
Keyword(s):  
Ischemic Stroke ◽  
Brain Injury ◽  
Animal Models ◽  
Inflammatory Response ◽  
Functional Outcomes ◽  
Animal Studies ◽  
Acute Inflammatory Response ◽  
Ischemic Brain Injury ◽  
Ischemic Brain ◽  
Neuron Apoptosis

AbstractEarly locomotor exercise after stroke has attracted a great deal of attention in clinical and animal research in recent years. A series of animal studies showed that early locomotor exercise poststroke could protect against ischemic brain injury and improve functional outcomes through the promotion of angiogenesis, inhibition of acute inflammatory response and neuron apoptosis, and protection of the blood-brain barrier. However, to date, the clinical application of early locomotor exercise poststroke was limited because some clinicians have little confidence in its effectiveness. Here we review the current progress of early locomotor exercise poststroke in animal models. We hope that a comprehensive awareness of the early locomotor exercise poststroke may help to implement early locomotor exercise more appropriately in treatment for ischemic stroke.

Photobiomodulation for Ischemic Brain Injury: Animal Models

2021 ◽  
Vol 89 (9) ◽  
pp. S67-S68
Author(s):  
Lorelei Tucker ◽  
Quanguang Zhang
Keyword(s):  
Brain Injury ◽  
Animal Models ◽  
Ischemic Brain Injury ◽  
Ischemic Brain

scholarly journals Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD IITM) for Acute Ischemic Brain Injury in Animal Models

2021 ◽  
Vol 26 ◽  
pp. 2515690X2110392
Author(s):  
I. G. M. Aswin R. Ranuh ◽  
Gadis Meinar Sari ◽  
Budi Utomo ◽  
Nur Setiawan Suroto ◽  
Asra Al Fauzi
Keyword(s):  
Systematic Review ◽  
Brain Injury ◽  
Animal Models ◽  
Meta Analysis ◽  
Experimental Studies ◽  
Mean Difference ◽  
Control Group ◽  
Ischemic Brain Injury ◽  
Ischemic Brain ◽  
Infarction Volume

Introduction. Moleac (MLC) 901 is a traditional Chinese medication approved by the Sino Food and Drug Administration in 2001 for treating stroke. This study aims to analyze the efficacy of MLC901 in animal stroke models after medial cerebral artery occlusion (MCAO). Methods. Literature selection was performed according to the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA) 2015. Inclusion criteria for the experimental studies were the use of animal models, publication in English between 1990 and 2020, information regarding the intervention technique used, and outcomes regarding the efficacy of MLC901 administration. Results. MLC901 administration resulted in significantly less infarction volume by a mean difference of 17.17 compared to the control group (p < .00001). The MLC901 group resulted in significant improvement in 5-bromo-20-deoxyuridine (BrdU)-positive cells expression by a mean difference of 662.79 (p < .00001) and neurological function, which was indicated by a mean difference in the Bederson Neurological Outcome Score of 1.40 (p < .00001). Conclusions. MLC901 administration in an animal stroke model resulted in a better reduction in infarction volume and improvement in BrdU expression and neurologic function. These data could help in further determining the efficacy of MLC901 for acute ischemic brain injury in humans.

Sign in / Sign up

Export Citation Format

Share Document